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The αβ T-cell coreceptor CD4 enhances immune responses more
than 1 million-fold in some assays, and yet the affinity of CD4
for its ligand, peptide-major histocompatibility class II (pMHC II)
on antigen-presenting cells, is so weak that it was previously un-
quantifiable. Here, we report that a soluble form of CD4 failed to
bind detectably to pMHC II in surface plasmon resonance-based
assays, establishing a new upper limit for the solution affinity at
2.5 mM. However, when presented multivalently on magnetic
beads, soluble CD4 bound pMHC II-expressing B cells, confirming
that it is active and allowing mapping of the native coreceptor
binding site on pMHC II. Whereas binding was undetectable in
solution, the affinity of the CD4/pMHC II interaction could be mea-
sured in 2D using CD4- and adhesion molecule-functionalized, sup-
ported lipid bilayers, yielding a 2D Kd of ∼5,000 molecules/μm2.
This value is two to three orders of magnitude higher than pre-
viously measured 2D Kd values for interacting leukocyte surface
proteins. Calculations indicated, however, that CD4/pMHC II bind-
ing would increase rates of T-cell receptor (TCR) complex phos-
phorylation by threefold via the recruitment of Lck, with only a
small, 2–20% increase in the effective affinity of the TCR for pMHC II.
The affinity of CD4/pMHC II therefore seems to be set at a value
that increases T-cell sensitivity by enhancing phosphorylation,
without compromising ligand discrimination.
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Tcells with αβ T-cell receptors (TCRs) comprise functionallydistinct subsets depending on which transcription factors and
which of two coreceptors, CD8 or CD4, they express. CD8+ T cells
respond to peptide agonists presented by major histocompatibility
class I molecules (pMHC I) and are cytotoxic, whereas conven-
tional CD4+ cells recognize peptide-MHC class II (pMHC II) and
provide “help” defined by the cytokines they secrete (1). Cell ad-
hesion assays explain this functionality insofar as CD8 and CD4
bind directly to pMHC I and pMHC II, respectively (2, 3). CD4
comprises two pairs of V-set and C2-set Ig superfamily domains,
with early mutational data showing that the “top” two domains
bind pMHC II (4). Crystal structures of cross-species and affinity-
matured CD4/pMHC II complexes suggest that CD4 binds a
pocket formed by the α2 and β2 domains of pMHC II (5, 6). The
role of coreceptors in heightening T-cell responses is well estab-
lished. For example, whereas CD4+ T-cells can respond to single
pMHC II complexes presented by antigen-presenting cells (APCs),
30 or more complexes are required if CD4 is blocked (7).
How CD4 achieves these effects, however, is incompletely
understood. Coreceptors are pivotal in recruiting the kinase Lck
to TCR/pMHC complexes (8, 9), but for reasons that are unclear
coreceptor/pMHC interactions are extraordinarily weak. Tradi-
tionally, weak protein interactions are characterized using surface
plasmon resonance (SPR) measurements, where one protein is
tethered to the sensor surface and over it the other is passed at
various concentrations. The SPR-based affinity of CD8 for pMHC I
is 50–200 μM (10). However, SPR has thus far failed to detect in-
teractions between CD4 and pMHC II, setting a lower limit of the
Kd at least two orders of magnitude higher than for typical inter-
acting leukocyte-expressed proteins (5, 10, 11).
Here, we use SPR assays to extend the upper limit of the CD4/
pMHC II solution affinity. However, the interactions of proteins
in solution may differ from those at contacts between two cells,
or between a cell surface and model lipid bilayer (11–14). We
therefore also analyzed the 2D affinity of the CD4/pMHC II
interaction for B cells interacting with supported lipid bilayers
(SLBs) containing fluorescently labeled CD4 and the small
T-cell adhesion protein CD2, used to create a physiological context
for CD4/pMHC II binding. CD2 is expressed by T cells and binds
CD58 on B cells with much higher affinity than the CD4/pMHC II
interaction (15, 16). Including CD2 ensured that CD4/pMHC II
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bonds had time to develop and reduced the risk of biasing the
data toward cells with high avidity for CD4 (15).
Other 2D Kd measurements have been made, but only for
systems where the average Kd is significantly lower than that of
CD4/pMHC II binding (12, 13, 16, 17). Here, we use the method
of Zhu et al. (16) to measure the 2D Kd for the CD4/pMHC II
interaction, which proves to the best of our knowledge to be the
weakest such interaction ever studied. The surface density of
CD4 bound to pMHC II on the B cell, B, is related to the surface
density of free CD4 in the SLB beneath the cell, F, by the Zhu–
Golan expression
B
F
=
Nt × f
Kd × Scell
−
B× p
Kd
, [1]
where Nt and f are the number and mobile fraction of pMHC II
molecules, respectively, Scell is the surface area of the cell, and p
is the ratio of the SLB/cell contact area to Scell. Measurements
were also made for rat CD2 and CD48 for comparison and as a
test of the CD4/pMHC II results. Finally, we consider why CD4/
pMHC II binding is so weak and develop a mathematical model
to investigate how it could affect the stability of TCR/pMHC II
complexes and affect rates of Lck recruitment and TCR phos-
phorylation. Our findings extend the known physical limits of
functional protein interactions at the cell surface.
Results
Binding of Soluble CD4 to pMHC II. We first tried to directly mea-
sure the binding affinity of CD4 for pMHC II molecules in SPR-
based assays. For this, soluble biotinylatable human CD4 (sCD4)
was expressed in mammalian cells (18) (Materials and Methods).
sCD4 bound stoichiometrically at distinct epitopes to two different
mouse anti-human CD4 antibodies (ADP318 and RPA-T4; Fig. S1
A and B), and it also bound to HIV-1 gp120 (Fig. S1C), indicating
that it was homogeneous and correctly folded. sCD4 was injected at
different concentrations at 37 °C over a sensor surface presenting
immobilized HLA-DRB1*01:01/DRA*01 (DR1) pMHC II bound
with influenza HA peptide or HLA-A*24:02 (A24) pMHC I bound
with a Dengue peptide (Den2) as a negative control (Fig. 1A).
The pMHC II proteins bound strongly to L243, a conformation-
sensitive, pan anti-human DR antibody (Fig. S2A), indicating
that the pMHC II was functional. However, even at exceptionally
high concentrations of sCD4 (up to 2.5 mM), no significant
difference in response was detectable between the control and
the pMHC II-containing flow cells (Fig. 1A). Injections at the
highest concentration (2.5 mM) at 4 °C (to minimize dissociation)
also gave no binding (Fig. S2B). These measurements were re-
peated with two other pMHC II, HLA-DRB1*15:01/DRA*01
(DR2) bound with MBP peptide and HLA-DRB1*04:01/DRA*01
(DR4) bound with EBV peptide, with the same outcome (Fig. S3).
To confirm that sCD4 could bind pMHC II we developed a
multivalent binding assay. DR1, the beta chain of which was
attached N-terminally to HA peptide and C-terminally to GFP
(i.e., HA-DR1-GFP; Fig. S4A), was expressed in HEK 293T
cells. Biotinylated sCD4 (sCD4biot) tetramerized with phycoer-
ythrin-labeled streptavidin (SA) bound strongly to HEK 293T
cells expressing HIV-1 gp120-GFP, but not to cells expressing
HA-DR1-GFP (Fig. S4B). sCD4biot avidity was then increased
by attaching it to SA-coated magnetic beads (∼50,000 sCD4biot
per bead) and used to “pull down” HA-DR1-GFP–expressing
cells (Fig. 1B; example bead-bound cells are shown in Fig. 1C).
Three- to fourfold more cells expressing HA-DR1-GFP could be
recovered than cells expressing the DR1β chain or GFP only
(Fig. 1B), demonstrating binding of sCD4 to HA-DR1-GFP.
However, this was only a quarter of the recoverable gp120-GFP–
expressing cells (Fig. 1B), emphasizing the very low affinity of
CD4/pMHC II binding. The interaction was sensitive to muta-
tions of residues clustered in the pocket between the α2 and β2
domains used by affinity-matured CD4 to bind DR1 and DR4
(19), that is, βI148, βL158, αT90, and αL92 (Fig. 2, Fig. S4C and
SI Text, Mutation Analysis of the CD4 Binding Site of DR1).
A
C
B
0
200
400
600
0
0 1 2 3
5
10
15
20
25
C
el
ls
 re
co
ve
re
d/
fie
ld
R
es
po
ns
e 
un
its
 (×
10
-3
)
GF
P o
nly
gp
12
0-G
FP
DR
1β
 on
ly
HA
-D
R1
-G
FP
sCD4 (mM)
A24/Den2
DR1/HA
Fig. 1. The interaction of CD4 with pMHC II in solution is very weak. (A) SPR
data showing the response when passing sCD4 over sensor surface pre-
senting immobilized biotinylated pMHC II molecules (DR1/HA; ○), or pMHC I
molecules (A24/Den2; ♢) as a control. (B) Number of isolated pMHC II (HA-
DR1-GFP)–expressing HEK 293T cells that bound to biotinylated sCD4-coated
beads. Error bars show ± one SEM. (C) A bright-field image of cells with
bound sCD4-coated beads (Left); white and black arrows identify individual
or clustered cells expressing or not expressing HA-DR1-GFP based on a cor-
responding fluorescence image (Right).
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Fig. 2. The native CD4 binding site of pMHC II. (A) The surface of HLA-DR1
(PDB ID code 3S4S) is shown over a ribbon representation of its secondary
structure (alpha chain in blue; beta in purple). The surface corresponding to
residues that are buried by CD4 in the complex is highlighted in yellow. (B) Two
orthogonal surface views showing residues whosemutation disrupts binding to
CD4 (red), and residues whose mutation has no effect (green). (C) Histogram
showing the numbers of cells recovered via the binding of CD4-coated mag-
netic beads, for each of the mutant proteins. Error bars show ± one SD.
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Mutations of residues analogous to those in pMHC I that bind
CD8, that is, βE137 and βV142, were disruptive, as noted pre-
viously (20), due perhaps to indirect effects on the structure of
the pocket. Mutations of αK126, αT129, and αT130 at a second
site proposed to allow CD4/pMHC II complex oligomerization
(21) were without effect, however, implying that CD4 does not
bind this region. Overall these data are consistent with native
CD4 binding pMHC II at the single site identified in structures
of cross-species and affinity-matured CD4/pMHC II complexes,
and with binding being undetectable in SPR experiments due to
the very low solution affinity of this interaction.
Binding of B Cells to CD4 in Lipid Bilayers. SLBs containing different
amounts of Alexa Fluor 647-labeled, lipid-anchored CD4 (400–
4,000 molecules/μm2) were used to investigate CD4/pMHC II
binding at the B-cell surface at room temperature (22 °C). Raji B
cells were added above the SLB and allowed to bind to the proteins
in the SLB. To ensure firm contact, and to position the cell surface
at physiologically relevant distances (22), ∼400 molecules/μm2 of
Alexa Fluor 488-labeled, lipid-anchored CD2 was incorporated
in the SLB. Movie S1 shows B cells settling on an SLB containing
900 molecules/μm2 of CD4 and 400 molecules/μm2 of CD2.
Three types of SLB/B-cell contacts formed (Fig. 3). Clear in-
creases in CD2 fluorescence beneath the cells are observed in all
three cases but, for case i, the CD4 intensity decreases compared
with outside the cell, whereas in cases ii and iii it increases
slightly (see also Fig. S5). The distribution of cases is i, 22 ± 15%;
ii, 52 ± 12%; and iii, 26 ± 11% (mean value ± one SD from 12
experiments), where, from Fig. S5, case i is defined as cells to the
left of the kink in the fitted curve and cases ii and iii as cells on
the lower and upper half of the slope, respectively. In case ii it is
also seen that under the cell, but outside the contact area given
by the CD2 image (dotted contour in the bright-field image, Fig.
3), the intensity is significantly lower compared with outside the
cell (see also SI Text, Kinetic Binding Theory). The reason for this
is that unbound CD4 is excluded from the cell–cell contact. Case
i corresponds to an SLB/B-cell contact where no amount of CD4
binding is discernible. This behavior is not limited to CD4
binding to B cells: CD4 depletion was observed in SLB contacts
formed by pMHC II nonexpressing Jurkat cells (Fig. S6A), and
rat CD2 added to the SLBs, which does not bind human B cells,
was depleted at B-cell contacts (Fig. S6B). However, in these cases
depletion only was observed, and not accumulation as observed for
the SLB with CD4/B-cell contacts (see cases ii and iii in Fig. 3),
indicating that CD4/pMHC II binding was being measured. Ligand
depletion observed elsewhere has been attributed to steric
crowding at the contact (17). This can significantly affect the
analysis of binding affinity using Eq. 1 if not corrected for, es-
pecially when B/F < 1 (16, 17) (see SI Materials and Methods, 2D
Affinity for details of how compensation was made).
Zhu–Golan Analysis of CD4/pMHC II Binding. The amount of CD4
accumulation under different cells on a given SLB varied con-
siderably (Fig. S5), with the SD of B/F for each experiment
being ∼70% of the mean. However, the mean value from dif-
ferent sets of experiments under similar conditions has a much
smaller spread and is fairly reproducible (Fig. 4). The variation
therefore results from differences between the cells and their
CD4 avidity rather than measurement uncertainty. Plotting the
mean value of B/F from each SLB resulted in the data shown
in Fig. 4 for CD4/pMHC II binding and for rat CD2 (35–
1,600 molecules/μm2) binding to rat CD48 [either WT or a weakly-
binding mutant Q40R (23)]. For the latter experiments CD48-
transfected Jurkat T cells were used and ∼100 molecules/μm2
of human CD58 was added to the SLBs to position the cells
(Fig. S6 C and D).
The experimental data were fitted to Eq. 1 with values of Nt
and Scell determined as described inMaterials and Methods (see
Table 1 for values), assuming a mobile fraction of f = 1. The
only free parameter to fit is then Kd. This gave the following
2D Kd values: 4,800 molecules/μm2 for CD4/pMHC II (see also
SI Text, Accuracy of the CD4/pMHC II 2D Kd), 38 molecules/μm2
for CD2/CD48 (WT), and 380 molecules/μm2 for CD2/CD48
(Q40R). To validate the analysis we also analyzed the rat CD2/
CD48 (WT) data using the standard Zhu–Golan method, where
the slope of the data in Fig. 4 is used to determine Kd without
knowing Nt, f, and Scell (16). The observation that the two values
were the same (38 molecules/μm2) indicated that our method of
analysis was approximately valid, at least for the rat CD2/CD48
case. We did not use the Zhu–Golan analysis for all datasets
because using the slope to determine the Kd value is less
accurate for the weaker interactions, because the slow change
in B/F vs. B × p is less than, or comparable to, the accuracy of
the measurements for those cases. This is less of a problem when
fixing Nt, f, and Scell, which gives more accurate values for Kd as-
suming that the error in choosing Nt, f, and Scell is not too large.
The 2D Kd value for WT rat CD2/CD48 binding is similar in
magnitude, but slightly smaller, than previous measurements
(15). The 2D Kd value for the weak-binding Q40R mutant is
10-fold larger than that for theWT, similar to the ratio in the 3D Kd
measurements (Table 1). These interactions are weak compared
with many other protein interactions between T cells and APCs, as
illustrated also by their relatively large 3D Kd values. However, the
CD4/pMHC II 2D Kd at 5,000 molecules/μm2 is one to two orders
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Fig. 3. Fluorescence images showing different degrees of accumulation of
CD4 and CD2 beneath the B cell shown in the bright-field images to the
right. The dashed line in the bright-field images shows the contour of the
SLB/cell contact identified by CD2 accumulation. The numbering i to iii cor-
responds to different cases of CD4 accumulation in the SLB/cell contact.
B×p (molecules/μm2)
B
/F
0 20 40 60 10080
0
1
2
3
4
5
B×p (molecules/μm2)
B
/F
0 40302010
0
0.1
0.2
0.3
0.4
Fig. 4. (Left) Zhu–Golan curves showing the relative accumulation of li-
gands for three different protein-pair interactions: rat CD2/CD48 (WT; +), rat
CD2/CD48 (Q40R;▼), and CD4/pMHC II (○). The solid lines are linear fits to
Eq. 1, with Nt × f and Scell fixed, yielding Kds for the different interactions.
(Right) The spread of CD4/pMHC II data across a smaller scale.
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of magnitude larger compared with these interactions, three orders
of magnitude larger than that for human CD2/CD58 binding (17),
and two to three orders of magnitude larger than that for TCR/
pMHC interactions (13, 24). The 3D Kd values for the latter in-
teractions is ∼10 μM (10, 13, 24, 25), so it can be expected that the
3D Kd for CD4/pMHC II binding should, similar to the 2D Kd, be
two to three orders of magnitude larger than this value. This is in
agreement with a lower limit of 2.5 mM for the 3D Kd of the CD4/
pMHC II interaction measured here using SPR, although extrinsic
factors such as the average distance between the two cell surfaces
could in principle significantly affect binding in 2D vs. 3D. Mea-
surements of the CD4/pMHC II 2D Kd were also made at 37 °C.
The B/F ratios from different SLBs were, within the accuracy of the
experiments, similar to those at room temperature.
A delimited area of the SLB/B-cell contact was bleached and
recovery studied to investigate the dynamic behavior of the CD4/
pMHC II interaction (Fig. S7). The fluorescence from free and
bound CD4 almost completely recovered within 2 min, indicating
that the amount of trapped CD4 in the contact is small compared
with the density of mobile molecules. From a fit of the recovery
data (Fig. S7B) an average diffusivity of D = 0.16 ± 0.06 μm2/s
(n = 4) was obtained for CD4 in the contact. This value is 10 times
smaller than that for free CD4 outside the contact (1.8 ± 0.2 μm2/s;
n = 4), most likely caused by a higher net drag on the protein in the
contact, rather than specific CD4 binding events (see SI Text,
Measure of CD4 Turnover Using Photobleaching for details).
Modeling of the Effects of CD4 on TCR/pMHC II Stability and
Phosphorylation Rate. Different mathematical expressions were
derived to investigate how the very weak CD4/pMHC II inter-
action affects T-cell sensitivity and the stability of ternary TCR/
pMHC II complexes.
Effect of CD4 on Lck recruitment to nonphosphorylated TCRs. CD4-
associated Lck (CD4-Lck) can only phosphorylate the TCR com-
plex when it is within a certain area, A, around the TCR/pMHC II.
It can be assumed that Lck is within area A when CD4-Lck binds
to pMHC II in a TCR/pMHC II pair, which means that bound
CD4-Lck can phosphorylate the TCR/pMHC II complex an extra
fraction Rt/Kc of the time (see SI Text, Recruitment of CD4-Lck to
Nonphosphorylated TCR/pMHC II for details), where Rt is the
density of CD4-Lck and Kc is the 2D Kd of the CD4/pMHC II
interaction. This results in the following formula for the overall
rate of TCR phosphorylation by CD4-Lck, for which the second
term is due to Lck recruitment:
kp,  CD4Lck=TCR = kp,  LCK=TCRð1+ σ=KcÞ, [2]
where kp, CD4-Lck/TCR and kp, Lck/TCR are the rates of TCR phos-
phorylation by CD4-Lck and Lck, respectively, and σ = 1/A is an
effective local concentration corresponding to one molecule
within area A. The actual size of A has not been experimentally
determined but is estimated to be of the order of 100 nm2, cor-
responding to σ = 10,000 molecules/μm2 (8, 9, 26). This is also
comparable to the area occupied by Lck in the CD4-Lck/TCR/
pMHC II complex (19). With Kc = 5,000 molecules/μm2, kp, CD4-Lck/
TCR is a factor of three larger than kp, Lck/TCR.
Effect of CD4 on the stability and phosphorylation of ternary CD4-Lck/
phosphorylated TCR/pMHC II complexes. Following TCR phosphory-
lation CD4-Lck can bind phosphorylated tyrosines in the TCR
complex (27). To investigate how this can affect the recruitment
of Lck and the stability of TCR/pMHC II in the ternary complex,
we developed a mathematical model describing the equilibrium
distribution of CD4-Lck, pMHC II, and phosphorylated TCR
(TCR-P) in different binding states (Fig. S8 and SI Text, Equi-
librium Models to Describe the Distribution of CD4-Lck, TCR-P,
and pMHC II). The number of TCR-P is assumed to be low early
in T-cell responses, such that most CD4-Lck molecules are not
bound to TCR-P. The increase in effective affinity of TCR for
pMHC II, 1/Keff, in the presence of CD4 can, under these condi-
tions, be shown to be (see SI Text, Equilibrium Models to Describe
the Distribution of CD4-Lck, TCR-P, and pMHC II for details)
1

Keff
1=K
=

1+
Rt
Kl
+
Rtσ
KcKl
+
RtK
KcKl

×

1+
Rt
Kl
−1
≈ 1+
Rtðσ +KÞ
KcKl
,
[3]
where Kl and K are the 2D Kd values for binding of CD4-Lck to
TCR-P and TCR-P to pMHC II, respectively. The parameter σ
corresponds again to the local concentration of bound molecules
in the complex (see also Eq. 2), which for simplicity was set to
be equal for all three interactions. It has been assumed in Eq. 3
that both the concentration of pMHC II and Rt are significantly
lower than Kc. The rightmost expression is approximately valid
when Rt/Kl < 1. Inserting σ = 10,000 molecules/μm2, Kc = 5,000
molecules/μm2, and Rt/Kl = 0.01–0.1 (see SI Text, Equilibrium
Models to Describe the Distribution of CD4-Lck, TCR-P, and
pMHC II for details on how Rt/Kl is estimated) into Eq. 3 gives
an apparent affinity increase of 2–20%, respectively, when K << σ.
CD4 will thus only modestly affect the stability of the TCR/
pMHC II interaction under these conditions.
Using the same assumptions and parameter values the in-
crease in recruitment of CD4-Lck to TCR-P due to CD4/pMHC
II binding can also be estimated. For Kl = 250 molecules/μm2
(28), the fraction of CD4-Lck–associated TCR-P/pMHC II in-
creases by 2.6- and 3.0-fold for Rt/Kl = 0.1 and Rt/Kl = 0.01,
respectively (see Eq. S18). The subsequent phosphorylation of
the TCR complex, as well as phosphorylation of recruited ZAP70,
will therefore also be increased by approximately threefold (see
Eq. S17). It should finally be noted that, from Eq. S17 and Eq. 2
this phosphorylation rate (kp,CD4-Lck/TCR-P) is 30–40 times larger
(depending on the value for Rt/Kl) than the initial rate of phos-
phorylation, that is, of the unphosphorylated receptor (kp,CD4-Lck/TCR
in Eq. 2).
Discussion
The binding of CD4 to pMHC II is remarkably weak compared
with the interactions of other molecules expressed by T cells and
APCs. Here, sCD4 monomers failed to bind pMHC II at con-
centrations as high as 2.5 mM, setting a new lower limit for the
solution Kd. To confirm that this measurement was reliable we
established a binding assay wherein, in a highly multivalent form,
sCD4 binding to cell-expressed pMHC II could be detected.
Table 1. Values for the 2D Kd analysis and corresponding solution (3D) Kd values
Quantity CD4/MHC II† CD2/CD48 (WT) CD2/CD48 (Q40R)
Nt 570,000 ± 180,000
‡ 95,000 ± 12,000 310,000 ± 50,000
Scell 550 ± 70 μm2 690 ± 50 μm2 500 ± 80 μm2
2D Kd 4,800 molecules/μm2 38 molecules/μm2 380 molecules/μm2
3D Kd >2.5 mM 37 μM 440 μM
†Protein in the SLB/protein in the contacting cell.
‡Values are presented as mean ± one SD.
Jönsson et al. PNAS | May 17, 2016 | vol. 113 | no. 20 | 5685
IM
M
U
N
O
LO
G
Y
A
N
D
IN
FL
A
M
M
A
TI
O
N
Using this assay we confirmed that for native CD4 the binding
site on pMHC II corresponds to that suggested by crystal structures
of cross-species and affinity-matured CD4/pMHC II complexes
(5, 6). It can therefore be assumed that native CD4 forms the
same “v-shaped” complex that affinity-matured CD4 forms with
TCR/pMHC II, wherein contact with the TCR is seemingly
precluded (19). It thus seems very unlikely that the ternary CD4/
pMHC II/TCR interaction is stabilized by direct interactions
between the extracellular domains of CD4 and the TCR.
To characterize binding in 2D approximating the conditions at
T-cell/APC contacts, we studied the interactions of B cells with
SLBs containing human CD4 and used CD2 to initially anchor and
then position the cell on the SLB at a physiologically relevant dis-
tance. Zhu–Golan analysis gave a 2D Kd of ∼5,000 molecules/μm2
for the CD4/pMHC II interaction, to our knowledge the largest
value ever reported for protein interactions at the cell surface. This
value is two to three orders of magnitude larger than typical in-
teractions between molecules expressed by T cells and APCs but is
still specific because CD4 in SLBs did not interact with cells lacking
pMHC II. Photobleaching measurements showed that CD4/pMHC
II binding is reversible, and that the mobility of CD4 in the contact is
more than 10-fold lower compared with outside the contact. Al-
though the 2D off-rate (koff) for the CD4/pMHC II interaction could
not be determined in the present experiments, it can be estimated to
be of the order of 250 s−1 (see SI Text, Estimation of Kinetic Rate
Constants for details). With a 2D Kd value of 5,000 molecules/μm2
this gives a 2D on-rate (kon) of 0.05 μm2 molecules−1·s−1, which
is comparable to that measured for protein–protein interactions
of higher affinity between T cells and APCs (13, 29). However,
the koff is orders of magnitude larger (12, 13, 29).
The 2D Kd value obtained here corresponds to the equilibrium
value when two cells, or lipid bilayers with proteins, are held with
their surfaces positioned relative to each other at a distance
similar to that in the synaptic contact between T cells and APCs.
Other techniques involving, for instance, micropipettes to peri-
odically bring cells containing the two proteins into contact (12,
30), have been used to study the binding kinetics of single bonds
when the cells are not aligned. However, including stronger
binding auxiliary molecules to align and position the contacting
surface, such as rat CD2/CD48 in this work, would be prob-
lematic in pipette-based experiments because the binding ki-
netics of the auxiliary molecules would dominate the overall
signal vs. that for the specific CD4/pMHC II interaction. The 2D
Kd value obtained for the CD4/pMHC II interaction could be
different when T cells contact APCs versus B cells contacting
SLBs containing CD4 and CD2. However, the observation that
the CD4/pMHC II interaction is orders of magnitude weaker
than typical T-cell/APC protein interactions is expected to hold.
What are the implications of the very large dissociation constant,
and how does CD4 so profoundly affect T-cell signaling? The im-
portant role of CD4 in vivo is believed to be the recruitment of Lck to
the TCR (8, 9, 31). The recruited Lck would phosphorylate immu-
noreceptor tyrosine-based activation motifs constituting an early step
of T-cell activation (8, 9). In agreement with this, Xu and Littman
(27) found that T-cell responses were significantly reduced if CD4
could not bind pMHC II, and that this depended on CD4-Lck being
able to bind phosphorylated tyrosines in the TCR. Huppa et al. (13)
and Hong et al. (30) also recently showed that CD4 has a negligible
effect on the affinity and lifetime of TCR/pMHC II complexes, in-
dicating that the primary role of CD4 is not TCR/pMHC II stabili-
zation. To see whether our measured affinity of CD4 for pMHC II
fits with these results we undertook numerical calculations to estab-
lish whether, in particular, (i) CD4 contributes to initial TCR phos-
phorylation (Fig. 5A) and (ii) how the CD4/pMHC II interaction
affects the effective affinity of the TCR for pMHC II and the re-
cruitment of Lck to previously phosphorylated TCRs (Fig. 5B).
The mathematical expressions showed that despite the very
low affinity of CD4 for pMHC II it is sufficiently strong to
increase the rate of phosphorylation of both unphosphorylated
and previously phosphorylated TCRs up to threefold due to the
recruitment of Lck. However, the effective affinity of the TCR
for pMHC II only increased marginally (2–20%) under the same
conditions, in agreement with previous experimental observa-
tions (13, 30). This indicates that the decrease in T-cell sensitivity
when CD4/pMHC II binding is blocked arises from a reduction
in TCR phosphorylation by Lck, rather than from destabilization
of TCR/pMHC II binding. It should, however, be noted that the
increase in Lck recruitment of a factor of three is significantly
less than the 10- to 100-fold decrease in sensitivity observed in
antibody blocking experiments when calcium and IL-2 signaling
are monitored (7, 32). A possible explanation for this is that the
increase in phosphorylation is magnified by the exponential lifetime
of the TCR/pMHC bond (26) as well as by the requirement for
multiple triggering events to act cooperatively in producing calcium
fluxes and downstream signaling (33). The derived expressions also
showed that the phosphorylation of previously phosphorylated
TCRs is significantly (30–40 times) faster than the phosphorylation
of unphosphorylated TCRs. This results from CD4-Lck binding to
TCR-P, explaining the observation by Xu and Littman (27) that
T-cell responses are significantly reduced when Lck cannot bind to
TCR-P. It also indicates that phosphorylation of the first tyrosine(s)
in the TCR complex is rate-limiting for TCR phosphorylation.
It needs to be emphasized that these calculations are only
approximations and their purpose is to illustrate how, even with
the low affinity we have measured, CD4/pMHC II binding can
augment T-cell signaling. However, it is also possible that CD4
function and signaling are rather more dependent on prior TCR/
pMHC II engagement, because this facilitates CD4 recruitment.
For example, the 2D Kd of the CD4/pMHC II interaction could
be lower due to suppressed membrane fluctuations and/or op-
timal positioning of pMHC II for CD4 binding (34) (Fig. S9).
Other processes, such as phosphorylation by tyrosine kinases not as-
sociated with CD4, might also affect initial signaling rates. It is fur-
thermore possible that because the local concentration of CD4-Lck is
increased in the immunological synapse (31), this could start to sta-
bilize TCR-P/pMHC II in the synapse according to Eq. 3, which would
also increase sensitivity. It is clear that more experiments are there-
fore needed to completely understand the role of CD4 in T-cell
activation, but our data provide two key insights. First, the in-
teraction of CD4 with pMHC II is very weak but measurable and
specific, and second, at this low affinity, CD4 binding can enhance
TCR phosphorylation without significantly stabilizing TCR/pMHC
binding. Too low a Kd for the CD4/pMHC II interaction would have
detrimental effects on the discrimination of self from nonself pep-
tides, whereas a too high Kd would result in too few interactions
with pMHC II molecules for signaling to be enhanced via the de-
livery of CD4-Lck to the binary TCR/pMHC II complex.
pMHC II
A B
TCR-P
Lck CD4-Lck
TCR VS VS
Fig. 5. The interaction between CD4 and pMHC II increases the phosphor-
ylation rate of TCR but has less influence on the TCR/pMHC II stability.
(A) Schematic illustrations showing how binding of CD4-Lck to pMHC II in-
creases the rate of initial TCR phosphorylation. (B) Binding of CD4-Lck to TCR-P
increases the rate of phosphorylation by recruitment of Lck but has only a
modest effect on the effective affinity of the TCR/pMHC II complex.
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Materials and Methods
The materials and methods used are summarized below; detailed information
is given in Supporting Information. Institutional review board approval was
not required for use of the human cell lines or DNA constructs referred to.
Solution Affinity and Bead-Binding Experiments. sCD4 protein and soluble,
biotinylatable forms of DR1/HA (residues 307–318:PKYVKQNTLKLA), DR2/
MBP (residues 85–99:ENPVVHFFKNIVTPR), DR4/EBV (residues 627–641:
TGGVYHFVKKHVHES), and A24/Den2 (residues 555–564:INYADRRWCF) were
produced as described previously (35, 36). For testing for binding to sCD4, the
biotinylated pMHC II was immobilized on Biacore streptavidin-coated chips at
levels of 1,600 response units (RU) (DR1/HA), 1,750 RU (DR2/MBP), and 1,840 RU
(DR4/EBV). A24/Den2, a kind gift of Tao Dong, University of Oxford, Oxford, was
immobilized as a negative control at 1,600–1,900 RU. The affinities of WT and
Q40R-mutated rat CD48 were measured as described previously (23).
For the bead-binding assay, HEK 293T cells were transfected with constructs
encoding fluorescent HA-DR1-GFP or gp120-GFP as a control (see SI Materials
and Methods, 3D Affinity for details). To generate CD4-coated beads 10 μg
biotinylated sCD4 protein was incubated with 6.7 × 106 magnetic streptavidin
beads M-280 (Dynal Biotech). HEK 293T cells were transiently transfected by
calcium phosphate precipitation with alpha and beta chain constructs to ex-
press WT or mutant HA-DR1-GFP molecules (Fig. S4) or gp120-GFP controls.
Following magnetic “pull-down,” cells were either viewed by fluorescence
microscopy and counted in duplicate microscope fields or absolute numbers of
cells recovered were determined using a hemocytometer.
2D Affinity Measurements.An SLB consisting of 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC) from Avanti Polar Lipids with 5–10 wt % of 1,2-
dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl]
(nickel salt) (DGS-NTA) (Avanti Polar Lipids) was formed by vesicle fusion. After
formation of the SLB the solution was exchanged with a protein mixture of
either (i) polyhistidine-tagged human CD2 (labeled with Alexa Fluor 488) and
human CD4 (labeled with Alexa Fluor 647) for the CD4/pMHC II measurements
or (ii) polyhistidine-tagged rat CD2 (labeled with Alexa Fluor 488) and human
CD58 (labeled with Alexa Fluor 647) for the CD2/CD48 measurements.
Raji B cells or Jurkat cells expressing either WT or weakly binding Q40R
mutant CD48 were added to the protein-coupled SLBs and were allowed to
settle for ∼60 min before imaging. Number of proteins on the cell surface,
Nt, was determined by flow cytometry and Quantibrite analysis with saturating
concentrations of PE-conjugated monoclonal antibodies (see SI Materials and
Methods, 2D Affinity for details).
Fluorescence imaging was performed in total internal reflection mode
with simultaneous imaging of the sample at 488 nm and 647 nm (see SI
Materials and Methods, 2D Affinity for details of the microscope setup).
Images of ∼50 cells were acquired for each SLB. SLB protein densities were
calculated using fluorescence correlation spectroscopy and the images were
analyzed as detailed in SI Materials and Methods, 2D Affinity to obtain B/F
and B×p. Scell was obtained from a bright-field image of the cell. Photo-
bleaching measurements were performed with the same microscopy setup
as described in SI Materials and Methods, 2D Affinity.
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